Sale

Telmisartan Market

Telmisartan Market Size, Share, Trends, Analysis, Forecast: By Strength: 20 mg, 40 mg, 80 mg; By Indication: Hypertension, Stroke, Cardiac Arrest, Others; By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032

Telmisartan Market Outlook

The telmisartan market size was valued at USD 3.57 billion in 2023, driven by the rising prevalence of cardiovascular diseases across the major markets. The market is expected to grow at a CAGR of 5.6% during the forecast period of 2024-2032, with the values likely to rise from USD 3.77 billion in 2024 to USD 5.83 billion by 2032.

 

Global Telmisartan Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Telmisartan: Introduction

Telmisartan is an angiostatin II receptor blocker used to treat hypertension (high blood pressure). It works by relaxing the blood vessels to facilitate better blood flow and is commonly used to prevent strokes, kidney issues, and heart attacks. It is available in tablet form and is ingested through the mouth. Common dosage sizes include 20 mg, 40 mg, and 80 mg, which may be prescribed based on the patient’s condition.

 

Telmisartan Market Analysis

The growth of the market is being driven by the prevalence and rise in diseases like hypertension and other cardiovascular diseases like strokes and cardiac arrests. The robust growth of the pharmaceutical sector is supplementing the growth of telmisartan to treat chronic diseases like those related to the cardiovascular system. Telmisartan works against high blood pressure by being effective in gene modification for insulin sensitization and regulating glucose and lipid metabolism. Significant contributions towards research and development (R&D) projects to explore the various benefits of telmisartan in the treatment of diabetic nephropathy and other kidney disorders are generating growth opportunities for industry growth. In addition, pharmaceutical manufacturers are working towards the development of generic versions of telmisartan medications to provide cost-effective treatment to patients suffering from hypertension and other cardiovascular diseases, consequently augmenting the telmisartan market growth.

 

With a deeper understanding of technology, rising advancements and growing demand for telmisartan, novel synthesizing methods have emerged in the market. Researchers have been using a high-yielding Suzuki reaction, which has increased the yield production up to 83%.

 

Global Telmisartan Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Telmisartan Market Segmentation

Market Breakup by Strength

  • 20 mg
  • 40 mg
  • 80 mg

 

Market Breakup by Indication

  • Hypertension
  • Stroke
  • Cardiac Arrest
  • Others

 

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan

 

Global Telmisartan Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Telmisartan Market Overview

With a high prevalence of cardiovascular diseases, North America has dominated the telmisartan market share in the historical period. The presence of key healthcare players and well-developed research infrastructure has majorly contributed to the market share. In addition, mergers and acquisitions amongst impactful companies to increase their product portfolio and offer better treatment solutions to patients have also impacted the market positively.

 

In Europe, the increasing integration of novel technologies into the medical ecosystem has contributed to substantial market growth. The presence of research and academic institutions also aids in the development of innovative solutions for the patients. The government of major countries like the United Kingdom, Spain, and France provide relevant awareness about cardiovascular diseases allowing them to opt for correct medications for their condition.

 

Telmisartan Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Novartis AG
  • Astellas Pharma Inc.
  • Nippon Boehringer Ingelheim
  • Abbott
  • Hema Pharmaceuticals Pvt. Ltd.
  • Pfizer Inc.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Limited
  • Glaxosmithkline (GSK)
  • Zydus Cadila
  • Teva Pharmaceutical Industries Ltd. (Actavis Generics)
  • Sanofi SA
  • Mylan N.V.
  • Cipla Inc.

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Strength
  • Indication
  • Distribution Channel
  • Region
Breakup by Strength
  • 20 mg
  • 40 mg
  • 80 mg
Breakup by Indication
  • Hypertension
  • Stroke
  • Cardiac Arrest
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Breakup by Region
  • United States 
  • EU-4 and the United Kingdom 
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Novartis AG
  • Astellas Pharma Inc.
  • Nippon Boehringer Ingelheim
  • Abbott
  • Hema Pharmaceuticals Pvt. Ltd.
  • Pfizer Inc.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Limited
  • Glaxosmithkline (GSK)
  • Zydus Cadila
  • Teva Pharmaceutical Industries Ltd. (Actavis Generics)
  • Sanofi SA
  • Mylan N.V.
  • Cipla Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Hypertension Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Hypertension Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Hypertension Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Hypertension Epidemiology (2017-2032)
        5.3.1    Germany Hypertension Epidemiology Forecast (2017-2032) 
        5.3.2    France Hypertension Epidemiology Forecast (2017-2032) 
        5.3.3    Italy Hypertension Epidemiology Forecast (2017-2032) 
        5.3.4    Spain Hypertension Epidemiology Forecast (2017-2032) 
        5.3.5    United Kingdom Hypertension Epidemiology Forecast (2017-2032)
    5.4    Japan Hypertension Epidemiology (2017-2032)
6    Telmisartan Market Overview – 7MM
    6.1    Telmisartan Market Historical Value (2017-2023) 
    6.2    Telmisartan Market Forecast Value (2024-2032)
7    Telmisartan Market Landscape – 7MM
    7.1    Telmisartan Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Telmisartan Product Landscape
        7.2.1    Analysis by Strength
        7.2.2    Analysis by Indication
        7.2.3    Analysis by Distribution Channel
8    Telmisartan Market Dynamics
    8.1    Market Drivers and Constraints
    8.2    SWOT Analysis
    8.3    Porter’s Five Forces Model
    8.4    Key Demand Indicators 
    8.5    Key Price Indicators
    8.6    Industry Events, Initiatives, and Trends  
    8.7    Value Chain Analysis
9    Telmisartan Market Segmentation – 7MM
    9.1    Telmisartan Market by Strength
        9.1.1    Market Overview
        9.1.2    20 mg
        9.1.3    40 mg
        9.1.4    80 mg
    9.2    Telmisartan Market by Indication
        9.2.1    Market Overview
        9.2.2    Hypertension
        9.2.3    Stroke
        9.2.4    Cardiac Arrest
        9.2.5    Others
    9.3    Telmisartan Market by Distribution Channel 
        9.3.1    Market Overview
        9.3.2    Hospital Pharmacies
        9.3.3    Retail Pharmacies
        9.3.4    Online Pharmacies
    9.4    Telmisartan Market by Region
        9.4.1    Market Overview
        9.4.2    United States 
        9.4.3    EU-4 and the United Kingdom 
            9.4.3.1    Germany 
            9.4.3.2    France 
            9.4.3.3    Italy 
            9.4.3.4    Spain 
            9.4.3.5    United Kingdom     
        9.4.4    Japan
10    United States Telmisartan Market 
    10.1    Telmisartan Market Historical Value (2017-2023)  
    10.2    Telmisartan Market Forecast Value (2024-2032) 
    10.3    Telmisartan Market by Indication 
11    EU-4 and United Kingdom Telmisartan Market 
    11.1    Telmisartan Market Historical Value (2017-2023)  
    11.2    Telmisartan Market Forecast Value (2024-2032)
    11.3    Germany Telmisartan Market Overview 
        11.3.1    Telmisartan Market by Indication 
    11.4    France Telmisartan Market Overview 
        11.4.1    Telmisartan Market by Indication 
    11.5    Italy Telmisartan Market Overview 
        11.5.1    Telmisartan Market by Indication 
    11.6    Spain Telmisartan Market Overview 
        11.6.1    Telmisartan Market by Indication 
    11.7    United Kingdom Telmisartan Market Overview 
        11.7.1    Telmisartan Market by Indication 
12    Japan Telmisartan Market 
    12.1    Telmisartan Market Historical Value (2017-2023)  
    12.2    Telmisartan Market Forecast Value (2024-2032)
    12.3    Telmisartan Market by Indication 
13    Regulatory Framework
14    Patent Analysis

    14.1    Analysis by Type of Patent
    14.2    Analysis by Publication year
    14.3    Analysis by Issuing Authority
    14.4    Analysis by Patent Age
    14.5    Analysis by CPC Analysis
    14.6    Analysis by Patent Valuation 
    14.7    Analysis by Key Players
15    Clinical Trials Analysis
    15.1     Analysis by Trial Registration Year
    15.2    Analysis by Trial Status
    15.3    Analysis by Trial Phase
    15.4    Analysis by Therapeutic Area
    15.5    Analysis by Geography
16    Funding and Investment Analysis
    16.1    Analysis by Funding Instances
    16.2    Analysis by Type of Funding
    16.3    Analysis by Funding Amount
    16.4    Analysis by Leading Players
    16.5    Analysis by Leading Investors
    16.6    Analysis by Geography
17    Partnership and Collaborations Analysis
    17.1    Analysis by Partnership Instances
    17.2    Analysis by Type of Partnership
    17.3    Analysis by Leading Players
    17.4    Analysis by Geography
18    Supplier Landscape
    18.1    Novartis AG
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Astellas Pharma Inc.
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    Nippon Boehringer Ingelheim
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Abbott
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Hema Pharmaceuticals Pvt. Ltd.
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Pfizer Inc.
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Aurobindo Pharma
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Sun Pharmaceutical Industries Limited
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Glaxosmithkline (GSK)
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Zydus Cadila
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    Teva Pharmaceutical Industries Ltd. (Actavis Generics)
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    Sanofi SA
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Mylan N.V.
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    Cipla Inc.
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
19    Telmisartan Market - Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 3.57 billion in 2023, driven by the rising incidence of cardiovascular diseases across major markets.

The market is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032, likely to reach a market value of USD 5.83 billion by 2032.

The high market demand is driven growing investments in the research and development (R&D) projects to explore the development of telmisartan in the treatment of diabetes and other chronic diseases as well.

Major market trends involve the application of synthetic methods to synthesize the medication.

Based on strength, the market is divided into 20 mg, 40 mg, and 80 mg.

Hypertension, stroke, and cardiac arrest, among others are some of the common indication types.

Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The major regions of the market include the United States, Japan, the United Kingdom, and EU-4. EU-4 is further segmented into Germany, France, Italy, Spain, and the United Kingdom.

Key players involved in the market are Novartis AG, Astellas Pharma Inc., Nippon Boehringer Ingelheim, Abbott, Hema Pharmaceuticals Pvt. Ltd., Pfizer Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Limited, Glaxosmithkline (GSK), Zydus Cadila, Teva Pharmaceutical Industries Ltd. (Actavis Generics), Sanofi SA, Mylan N.V. and Cipla Inc.

Purchase Full Report

Mini Report

$ 3332     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6110     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8332     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9999     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER